Top

International Journal of Clinical Oncology

Published in:

01-04-2017 | Original Article

Clinical outcomes of second transurethral resection in non-muscle invasive high-grade bladder cancer: a retrospective, multi-institutional, collaborative study

Authors: Naoto Kamiya, Hiroyoshi Suzuki, Takahito Suyama, Masayuki Kobayashi, Satoshi Fukasawa, Nobuyuki Sekita, Kazuo Mikami, Naoki Nihei, Yukio Naya, Tomohiko Ichikawa

Published in: International Journal of Clinical Oncology | Issue 2/2017

Abstract

Background

A retrospective, multi-institutional collaborative study was conducted to evaluate the impact of second transurethral resection (TUR) on the clinical outcome of non-muscle invasive high-grade bladder cancer and to identify predictors of invasion to the lamina propria (pT1) or deeper and residual tumor at the second TUR.

Methods

The clinical and pathological features of 198 patients with non-muscle invasive high-grade bladder cancer treated in five medical institutions from April 1990 to March 2013 were reviewed retrospectively. All patients underwent a second TUR within a mean of 1.5 months after the first resection. Clinicopathological findings of the first and second TURs were compared. Cancer-specific survival and recurrence-free survival were evaluated. Univariate and multivariate analyses for predictors of residual cancer at the second TUR were performed using a logistic regression model.

Results

At the second TUR, no tumor was found in 111 (56 %) patients, and 87 (44 %) had residual cancer. At the first TUR, five pT1 patients (3 %) were upstaged to pT2, one pTa patient (1 %) was upstaged to pT1, and 12 G2 patients (6 %) had their tumor upgraded to G3. Patients the group with less than stage pT1 cancer at the second TUR had significantly better survival than those in the group with stage pT1 or deeper cancer. Tumor multiplicity at the first resection was an independent risk factor for pT1 or deeper tumor at the second TUR.

Conclusion

A second TUR is a valuable diagnostic procedure for accurate staging of non-muscle invasive high-grade bladder cancer. Tumor multiplicity at the first TUR was a significant independent predictor of pT1 or deeper tumor at the second TUR.

Kakehi Y, Hirao Y, Kim WJ et al (2010) Bladder Cancer Working Group report. Jpn J Clin Oncol 40:57–64CrossRef

Kitamura H, Kakehi Y (2015) Treatment and management of high-grade T1 bladder cancer: what should we do after second TUR? Jpn J Clin Oncol 45:315–322CrossRefPubMed

Burger M, Catto JW, Dalbagni G et al (2013) Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63:234–241CrossRefPubMed

Babjuk M, Burger M, Zigeuner R et al (2013) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 64:639–653CrossRefPubMed

Kirkali Z, Chan T, Manoharan M et al (2005) Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66:4–34CrossRefPubMed

Herr HW (1999) The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 162:74–76CrossRefPubMed

Schips L, Augustin H, Zigeuner RE et al (2002) Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology 59:220–223CrossRefPubMed

Divrik RT, Sahin AF, Yildirim U et al (2010) Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomized clinical trial. Eur Urol 58:185–190CrossRefPubMed

Vianello A, Costantini E, Del Zingaro M et al (2011) Repeated white light transurethral resection of the bladder in nonmuscle-invasive urothelial bladder cancers: systematic review and meta-analysis. J Endourol 25:1703–1712CrossRefPubMed

10.

National Comprehensive Cancer Network (NCCN) (2015) Clinical practice guidelines in oncology (NCCN Guidelines®). Bladder Cancer Version2. http://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf. Accessed May 2015

11.

European Association of Urology (EAU) (2015) Oncology guidelines (EAU Guidelines®). Non-muscle-invasive Bladder Cancer (Ta, T1 and CIS) http://uroweb.org/wp-content/uploads/EAU-Guidelines-Non-muscle-invasive-Bladder-Cancer-2015-v1.pdf. Accessed Mar 2015

12.

Hall MC, Chang SS, Dalbagni G et al (2007) Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 178:2314–2330CrossRefPubMed

13.

Nieder AM, Brausi M, Lamm D et al (2005) Management of stage T1 tumors of the bladder: International Consensus Panel. Urology 66:108–125CrossRefPubMed

14.

Cookson MS, Herr HW, Zhang ZF et al (1997) The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 158:62–67CrossRefPubMed

15.

Kulkarni GS, Hakenberg OW, Gschwend JE et al (2010) An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol 57:60–70CrossRefPubMed

16.

van Rhijn BW, Burger M, Lotan Y et al (2009) Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 56:430–442CrossRefPubMed

17.

Bertz S, Denzinger S, Otto W et al (2011) Substaging by estimating the size of invasive tumour can improve risk stratification in pT1 urothelial bladder cancer-evaluation of a large hospital-based single-centre series. Histopathology 59:722–732CrossRefPubMed

18.

Roupret M, Seisen T, Comperat E et al (2013) Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: French national multicenter study with central pathology review. J Urol 189:2069–2076CrossRefPubMed

19.

Andius P, Johansson SL, Holmang S (2007) Prognostic factors in stage T1 bladder cancer: tumor pattern (solid or papillary) and vascular invasion more important than depth of invasion. Urology 70:758–762CrossRefPubMed

20.

Lamm D, Persad R, Brausi M et al (2014) Defining progression in nonmuscle invasive bladder cancer: it is time for a new, standard definition. J Urol 191:20–27CrossRefPubMed

21.

Pasin E, Josephson DY, Mitra AP et al (2008) Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev Urol 10:31–43PubMedPubMedCentral

22.

van Rhijn BW, van der Kwast TH, Alkhateeb SS et al (2012) A new and highly prognostic system to discern T1 bladder cancer substage. Eur Urol 61:378–384CrossRefPubMed

23.

Kunieda F, Kitamura H, Niwakawa M et al (2012) Watchful waiting versus intravesical BCG therapy for high-grade pT1 bladder cancer with pT0 histology after second transurethral resection: Japan Clinical Oncology Group Study JCOG1019. Jpn J Clin Oncol 42:1094–1098CrossRefPubMed

24.

Edge SB, Byrd DR, Compton CC et al (eds) (2010) AJCC cancer staging manual, 7th edn. Springer, New York

25.

Mostofi FK, Sobin LH, Torloni H (1973). Histological typing of urinary bladder tumors. World Health Organization, Geneva 1973

26.

Grimm M-O, Steinhoff CH, Simon X et al (2003) Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 170:433–437CrossRefPubMed

27.

Lazica DA, Roth S, Brandt AS et al (2014) Second transurethral resection after Ta high-grade bladder tumor: a 4.5-year period at a single university center. Urol Int 92:131–135CrossRefPubMed

28.

Herr HW, Donat SM (2008) Quality control in transurethral resection of bladder tumours. BJU Int 102:1242–1246CrossRefPubMed

29.

Shindo T, Masumori N, Kitamura H et al (2014) Clinical significance of definite muscle layer in TUR specimen for evaluating progression rate in T1G3 bladder cancer: multicenter retrospective study by the Sapporo Medical University Urologic Oncology Consortium (SUOC). World J Urol 32:1281–1285CrossRefPubMed

30.

Takaoka E, Matsui Y, Inoue T et al (2013) Risk factors for intravesical recurrence in patients with high-grade T1 bladder cancer in the second TUR era. Jpn J Clin Oncol 43:404–409CrossRefPubMed

31.

Segal R, Yafi FA, Brimo F et al (2012) Prognostic factors and outcome in patients with T1 high-grade bladder cancer: can we identify patients for early cystectomy? BJU Int 109:1026–1030CrossRefPubMed

32.

Dalbagni G, Vora K, Kaag M et al (2009) Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. Eur Urol 56:903–910CrossRefPubMed

Title: Clinical outcomes of second transurethral resection in non-muscle invasive high-grade bladder cancer: a retrospective, multi-institutional, collaborative study
Authors: Naoto Kamiya
Hiroyoshi Suzuki
Takahito Suyama
Masayuki Kobayashi
Satoshi Fukasawa
Nobuyuki Sekita
Kazuo Mikami
Naoki Nihei
Yukio Naya
Tomohiko Ichikawa
Publication date: 01-04-2017
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 2/2017
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-016-1048-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2017

Biphasic decline in renal function after radical cystectomy with urinary diversion

Incidence of hypophosphatemia in advanced cancer patients: a recent report from a single institution

Recent progress and perspectives on prostate cancer biomarkers

Multi-institutional phase II study on the feasibility of liver resection following preoperative mFOLFOX6 therapy for resectable liver metastases from colorectal cancers

Combined antitumor effect of γ-secretase inhibitor and ABT-737 in Notch-expressing non-small cell lung cancer

Multidisciplinary evaluation at baseline and during treatment improves the rate of compliance and efficacy of deferasirox in elderly myelodysplastic patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer